Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
February 15, 2008
Development of a discriminating in vitro dissolution method for a poorly soluble NO-donating selective cyclooxygenase-2 inhibitor
Robert Papp, Pauline Luk, Wayne M Mullett, et al.
Journal of Cardiovascular Electrophysiology
|
January 13, 2006
Isolation of pulmonary veins using a transvenous curvilinear cryoablation catheter: feasibility, initial experience, and analysis of recurrences
Allan C Skanes, Steen M Jensen, Robert Papp, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 20, 2024
Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib
Robert Papp, Laird Trimble, Adrian J Fretland, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 17, 2010
The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors
Renee Aspiotis, Denis Deschênes, Daniel Dubé, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 26, 2011
Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents
Jean-François Lévesque, Kelly Bleasby, Amandine Chefson, et al.
Molecular Cancer Therapeutics
|
May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Anran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Nature Cancer
|
February 5, 2022
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Salomé Adam, Silvia Emma Rossi, Nathalie Moatti, et al.
Molecular Cancer Therapeutics
|
December 16, 2021
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston, Michal Zimmermann, Robert Papp, et al.
Journal of Medicinal Chemistry
|
July 26, 2022
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306
Janek Szychowski, Robert Papp, Evelyne Dietrich, et al.
Journal of Medicinal Chemistry
|
February 1, 2024
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
W Cameron Black, Abbas Abdoli, Xiuli An, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Journal of Pharmaceutical and Biomedical Analysis
|
February 15, 2008
Development of a discriminating in vitro dissolution method for a poorly soluble NO-donating selective cyclooxygenase-2 inhibitor
Robert Papp, Pauline Luk, Wayne M Mullett, et al.
Journal of Cardiovascular Electrophysiology
|
January 13, 2006
Isolation of pulmonary veins using a transvenous curvilinear cryoablation catheter: feasibility, initial experience, and analysis of recurrences
Allan C Skanes, Steen M Jensen, Robert Papp, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 20, 2024
Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib
Robert Papp, Laird Trimble, Adrian J Fretland, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 17, 2010
The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors
Renee Aspiotis, Denis Deschênes, Daniel Dubé, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 26, 2011
Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents
Jean-François Lévesque, Kelly Bleasby, Amandine Chefson, et al.
Molecular Cancer Therapeutics
|
May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Anran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Nature Cancer
|
February 5, 2022
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Salomé Adam, Silvia Emma Rossi, Nathalie Moatti, et al.
Molecular Cancer Therapeutics
|
December 16, 2021
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston, Michal Zimmermann, Robert Papp, et al.
Journal of Medicinal Chemistry
|
July 26, 2022
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306
Janek Szychowski, Robert Papp, Evelyne Dietrich, et al.
Journal of Medicinal Chemistry
|
February 1, 2024
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
W Cameron Black, Abbas Abdoli, Xiuli An, et al.
Page
of 3